Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report published on Monday morning,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Separately, Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $9.20.

Gossamer Bio Stock Down 5.6 %

NASDAQ GOSS opened at $0.77 on Monday. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.60. The company has a fifty day moving average of $0.94 and a 200-day moving average of $0.86. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. On average, research analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

Several hedge funds and other institutional investors have recently bought and sold shares of GOSS. SG Americas Securities LLC purchased a new stake in Gossamer Bio during the 1st quarter valued at $34,000. US Bancorp DE bought a new position in shares of Gossamer Bio during the third quarter valued at about $39,000. Choreo LLC purchased a new stake in shares of Gossamer Bio during the second quarter worth about $46,000. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the third quarter worth about $67,000. Finally, Algert Global LLC purchased a new position in Gossamer Bio during the 2nd quarter valued at about $75,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.